Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Merck & Co., Inc. filings on SEC EDGAR ↗
Merck & Co EVP&Pres, Merck Animal Heallth Richard R. DeLuca Sells $8.61M of Stock
Richard R. DeLuca, EVP&Pres, Merck Animal Heallth, sold 58,185 shares of Merck & Co., Inc. at $148.01 a share, worth $8.61M in total on Nov 12, 2026. Shares held after the trade: 112,955 (-34.0%).
Merck reported third-quarter 2026 worldwide sales of $18.1 billion, representing 5% growth driven by strong performance in oncology and animal health. The company narrowed and raised its full-year 2026 sales outlook to a range of $66.8 billion to $67.3 billion and highlighted clinical progress in its late-stage pipeline, including pivotal data for sac-TMT and its therapeutic cancer vaccine collaboration with Moderna.
Term
Q3 2026
“Our science-led strategy is transforming our business. The potentially practice-changing advances in oncology presented at last weekend’s ESMO meeting, including new data for our antibody-drug conjugate sac-TMT and the first Phase 3 validation of a therapeutic cancer vaccine, further clinically de-risk the substantial long-term opportunity of our late-phase pipeline. With positive momentum across multiple therapeutic areas, I’m increasingly confident in our ability to deliver long-term value for patients and shareholders.”
Robert M. Davis, chairman and chief executive officer
Merck & Co., Inc. has elected Paul J. Diaz to its Board of Directors, effective November 1, 2026. Mr. Diaz, a managing partner at Cressey & Company and former CEO of Myriad Genetics and Kindred Healthcare, will serve on the Audit and Research Committees. His appointment increases the Merck board to 14 members ahead of his formal shareholder election in May 2027.